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Abstract
Alterations in the metabolism of iron and its accumulation in the substantia nigra pars compacta accompany the pathogenesis of
Parkinson’s disease (PD). Changes in iron homeostasis also occur during aging, which constitutes a PD major risk factor. As such,
mitigation of iron overload via chelation strategies has been considered a plausible disease modifying approach. Iron chelation,
however, is imperfect because of general undesired side effects and lack of specificity; more effective approaches would rely on
targeting distinctive pathways responsible for iron overload in brain regions relevant to PD and, in particular, the substantia nigra.
We have previously demonstrated that the Transferrin/Transferrin Receptor 2 (TfR2) iron import mechanism functions in nigral
dopaminergic neurons, is perturbed in PD models and patients, and therefore constitutes a potential therapeutic target to halt iron
accumulation. To validate this hypothesis, we generated mice with targeted deletion of TfR2 in dopaminergic neurons. In these
animals, we modeled PD with multiple approaches, based either on neurotoxin exposure or alpha-synuclein proteotoxic
mechanisms. We found that TfR2 deletion can provide neuroprotection against dopaminergic degeneration, and against PD- and
aging-related iron overload. The effects, however, were significantly more pronounced in females rather than in males. Our data
indicate that the TfR2 iron import pathway represents an amenable strategy to hamper PD progression. Data also suggest,
however, that therapeutic strategies targeting TfR2 should consider a potential sexual dimorphism in neuroprotective response.
Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
primarily affecting dopaminergic (DA) neurons in the
nigrostriatal circuits of the basal ganglia. The disorder is
mainly idiopathic and less than 10% of cases are attributable
to monogenic causes. PD etiopathology is intricate and
involves complex gene–environment interactions perturbing
cellular functions at multiple levels [1]; the main disease
risk factor is aging [2, 3]. Mitochondrial dysfunction, alpha-
synuclein aggregation and consequent proteotoxic stress,
and noxious oxidant stress have been identified as central
pathogenic mechanisms [4]. At present, however, PD
remains intractable and therefore identification of specific
pathways that can be targeted to modify disease progression
remains of primary importance.
Perturbation of iron metabolism and consequent deposi-
tion of iron in the substantia nigra pars compacta (SNpc)
and in its DA neurons occur in both idiopathic and genetic
PD [5–9]. These alterations may have profound neuro-
pathological relevance; iron is essential for the function of
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mitochondria [10], it promotes aggregation of alpha-
synuclein [11], and favors production of oxidant species [12].
Increasing evidence indicates that, rather than being a
mere epiphenomenon, iron dysregulation actively con-
tributes to PD pathogenesis. Chelation experiments to
reduce iron bioavailability, for instance, successfully
oppose neuronal damage in animal models [13, 14]. Clinical
evidence further supports this relationship and recent phase
II clinical trials demonstrated that administration of the iron
chelator deferiprone effectively lowered motor decline in
patients [13, 15]. Altogether this evidence indicates that
restoration of iron homeostasis may represent an effective
therapy for PD. Iron chelation, however, is an imperfect
strategy to restore iron homeostasis, at least in this particular
disorder. Besides its general adverse side effects [16], iron
chelation has been conceived to treat diseases with systemic
iron overload, which does not occur in PD. Because body
and brain total iron levels are unaltered in PD, PD iron
changes rather result from a selective accumulation of the
metal in the SN [17]. Thus, while systemic chelation may
result in depletion of bioavailable iron with severe con-
sequences for the organism, iron overload in PD may be
better treated by targeting those mechanisms specifically
responsible for metal accumulation in the SNpc.
We have previously used a pesticide-induced PD model to
investigate the effects of PD-related environmental agents on
iron metabolism in rats and nonhuman primates [18]. We
found that toxin-induced neurodegeneration is associated with
progressive increase in the levels and oxidation of transferrin
(Tf)—the principal iron transporter in the body—within DA
neurons. Such increase is paralleled by iron accumulation.
Intracellular levels of Tf reflect the trafficking mediated by its
receptors and, thus far, two receptor isoforms have been
identified. Transferrin receptor 1 (TfR1) has an iron respon-
sive element (IRE) in its 3′UTR and therefore, is directly
regulated by intracellular iron levels; on the other hand, the
Transferrin Receptor 2 (TfR2) does not possess an IRE and is
regulated by means other than iron, possibly involving the
hormone hepcidin [19, 20]. Analyses of both tissue from PD
animal models and autoptic tissue from patients revealed that
TfR2, rather than TfR1, is highly expressed in DA neurons
[18]. Importantly, we also demonstrated that, within DA
neurons, the Tf/TfR2 system delivers iron to mitochondria via
endosome-mitochondria interactions, possibly via a kiss-and-
run mechanism as described in other cell types [21–23].
Based on these findings, we concluded that the Tf/TfR2 axis
is a major mechanism for iron transport into DA neurons and
hypothesized that its perturbation may enhance vulnerability
to neurodegenerative processes and therefore act as a PD risk
factor. Support in favor of this hypothesis came from the
results of an epidemiological study that analyzed three dif-
ferent PD cohorts to explore association between variants in
genes involved in iron metabolism and PD [24]. Tf and TfR2
were the only two genes showing, respectively, significant
and suggestive significant—as defined in [25]—protective
association with PD; importantly, in one of the cohorts, TfR2
reached significance. This genetic study substantiates our
previous laboratory discoveries in animal models and PD
brain autopsy tissues, and further strengthen the hypothesis
that the Tf/TfR2 axis may participate in PD pathogenesis.
To further test the relevance of the Tf/TfR2 iron import
mechanism to PD pathogenesis, we modeled the disease in
control mice and mutant animals with targeted TfR2 dele-
tion in neurons expressing tyrosine hydroxylase (TH)—
including SNpc DA neurons. In these mice, degeneration of
nigral neurons was achieved after exposure to the neuro-
toxicant MPTP, overexpression of α-synuclein (a protein
involved in PD pathogenesis) or intraparenchymal injec-
tions of pre-formed alpha-synuclein fibrils (PFF). We trea-
ted male and female animals as different experimental
groups because clinical evidence and large data meta-
analysis demonstrate sexual dimorphism in PD and gender
differences are also seen iron metabolism [26–28]. Here, we
demonstrate that TfR2 ablation provides neuroprotection in
animal models of PD and that this effect is gender-
dependent and significantly more pronounced in female as
compared to male mice.
Results
Generation of TfR2 conditional mutants and PD
modeling
Mutant mice with targeted deletion of TfR2 were generated
using the recombinase Cre:loxP system and crossing TfR2-
floxed mice [29] with a transgenic mice expressing the
recombinase under the TH promoter [30]. In the derived
strain (TfR2fl/fl:TH-Cre+/−), TfR2 is deleted in catechola-
minergic neurons, including dopamine neurons of the SNpc.
Because Cre-driven recombination may be variable even
among littermates [31], gene deletion was confirmed in
every single mouse used in the study by PCR on genomic
DNA [29] extracted from the olfactory bulb, which is rich in
DA neurons (Fig. 1A and Supplementary Fig. 1A). More-
over, breeding pairs were set up so that the Cre+/− trans-
gene was always transmitted by the mother because
recombination activity may vary depending upon the gender
of the supplying parent [31].
The different PD-related treatments involved in the
study–i.e., sub-acute MPTP injection, rAAV-mediated
human alpha-synuclein overexpression (rAAV), and infu-
sion of PFF—successfully induced DA degeneration, as
indicated by unbiased stereological counts (Fig. 1B).
Because aging is a main risk factor for PD, PD-like neu-
rodegeneration was also induced by MPTP administration
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to 52-week-old animals. Initial experiments revealed that
the MPTP paradigm used in younger animals (30 mg/kg)
induced very high mortality (<80%) in older mice. In the
latter, we therefore used a lower MPTP dose (17.5 mg/kg)
that elicited significant DA cell degeneration with no or
minimal mortality.
Targeted TfR2 deletion in TH+ cells alleviates
neuropathology in the MPTP model
In 12-week-old female mice, TfR2 deletion caused sig-
nificant neuroprotection, as evidenced by increased immu-
noreactivity of striatal TH (Fig. 2A) and higher counts of
nigral DA cell bodies in TfR2fl/fl:TH-Cre+/− mice (Fig. 2B).
These effects did not occur, however, in male mice, in
which no evidence of neuroprotection was observed at the
levels of both striatal terminals and nigral cell bodies. Perls
staining to evaluate Fe3+ levels revealed that TfR2 deletion
led to a significant reduction of ferric iron in both MPTP-
treated males and females (Fig. 2C).
Findings in 52-week-old female mice were similar to
those in younger animals; following MPTP exposure, TfR2
deletion ameliorated neuropathology, as indicated by
enhanced striatal innervation (Fig. 3A), and a higher num-
ber of DA cell bodies in the SNpc of TfR2fl/fl:TH-Cre+/−
mice (Fig. 3B). In MPTP-treated males, TfR2 ablation
slightly improved striatal innervation, but had no effect on
DA cell body loss.
In agreement with earlier studies [32], older control mice—
vehicle-treated—displayed higher basal ferric iron levels in
the ventral mesencephalon when compared to younger ani-
mals (Fig. 3C). Similar to the results in younger mice, reduced
iron accumulation was observed in TfR2fl/fl:TH-Cre+/− in both
MPTP-treated females and males. Double staining – i.e. Perls’
staining combined with TH immunocytochemistry - con-
firmed increased iron levels within DA neurons of the SNpc
(Fig. 3D); this effect was remarkably more evident in
52- week than in 12-week-old animals.
In conclusion, targeted deletion of TfR2 reduced toxin-
and age-induced ferric iron accumulation in the ventral
mesencephalon. It also conferred neuroprotection against
MPTP-induced nigrostriatal damage, but did so primarily in
young and old female mice.
Effects of targeted TfR2 deletion in TH+ cells in
synucleinopathy models of PD
We next evaluated the protective potential of TfR2 deletion
in two synucleinopathy models, namely in (1) mice in
which human alpha-synuclein overexpression was induced
by a stereotaxic injection of recombinant adeno-associated
(rAAV) viral vectors in the substantia nigra [33], and (2)
mice in which alpha-synuclein PFF were stereotaxically
injected in the striatum [34].
As expected, rAAV-transduced mice displayed a con-
spicuous accumulation of striatal human alpha-synuclein
(i.e., exogenous alpha-synuclein coded by rAAVs) in the
ipsilateral hemisphere that was paralleled by a considerable
reduction of DA innervation (Fig. 4A). Measurements of
striatal TH levels on the side of the brain ipsilateral to the
rAAV injection showed no significant differences between
mice with and without TfR2 deletion (Fig. 4B). Similarly,
stereological counts of ipsilateral nigral neurons revealed a
loss of cells that was comparable between control and
Fig. 1 Targeted TfR2 deletion in TH expressing cells and PD
modeling in mice. A PCR to confirm TfR2 deletion performed on
genomic DNA extracted from 30-μm-thick PFA-fixed sections of the
olfactory bulbs, which abound in TH-neurons. DNA from two con-
secutive slices was used in each PCR reaction. Genotyping was per-
formed using two different sets of primers, one of which (TfR2)
amplifies the WT or floxed allele, while the other (TfR2 deleted)
amplifies the deleted allele. Selective recombination of TfR2 selec-
tively occurs only in Cre-expressing floxed mice (Tfr2fl/flTH:Cre+/−,
last lane) and not in mice lacking Cre expression (lanes 2 and 4).
B Validation of the PD-related treatments used in the study, which
successfully elicited dopaminergic degeneration, as indicated by
unbiased stereological counts. Graphs represent mean+ SEM, two-
tailed Student’s t test; *p < 0.05, **p < 0.005, ***p < 0.001.
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TfR2fl/fl:TH-Cre+/− animals (Fig. 4C). Of note, ipsilateral
TH and cell count values were quite variable, probably
reflecting the variability of human alpha-synuclein expres-
sion among rAAV-injected animals (Supplementary Fig. 2).
Assessment of iron levels in this rAAV model was rela-
tively inconsistent, mostly because the Fe3+ Perls’ staining
often marked the site and followed the track of stereotaxic
injection, even at 6 months after surgery (Supplementary
Fig. 3, arrowheads). In a few animals, iron staining revealed
a pattern of nigral accumulation (Fig. 4A, Supplementary
Fig. 3, asterisks) whereas, in the other mice, iron deposition
was less evident in the ventral midbrain, and the signal was
primarily present along the needle track (arrow).
The final set of experiments was aimed at evaluating the
effects of TfR2 deletion in mice in which nigral cell
degeneration was triggered by a stereotaxical injection of
alpha-synuclein PFF in the striatum (Fig. 5A). As compared to
the rAAV model, the paradigm of striatal PFF infusion is
characterized by a nigrostriatal injury that is more moderate
and evolves in a relatively more progressive fashion [34].
These features were taken into consideration when we decided
to perform our analyses at 4 months after the PFF injection.
Data showed that TfR2 deletion was associated with an
increase in striatal TH immunoreactivity in both female and
male mice and with a significant protective effect against
nigral DA cell loss only in female animals (Fig. 5B, C). Perls’
staining combined with immunodetection of TH-positive
neurons showed increased iron levels within SNpc
dopamine neurons as a result of PFF administration. No dif-
ferences in total iron levels were detected, however, between
Fig. 2 TfR2 deletion is protective in 12-week-old MPTP-treated
mice. A TH immunoreactivity in striata of MPTP or vehicle-treated
animals. TfR2 deletion mitigates striatal denervation in brains of
female mice. B Unbiased stereological counts of TH immunopositive
neurons in the substantia nigra confirm that TfR2 targeted deletion is
protective in 12-week-old females, but not in males. C Perls’ staining
for Fe3+ reveals reduced iron accumulation in the midbrain after
MPTP treatment in animals with TfR2 targeted deletion (12-week-old
mice). Data in experimental groups are expressed as percentage of the
respective TfR2fl/flTH:Cre−/− vehicle-treated control group. Two-tailed
Student’s t test; *p < 0.05, **p < 0.005, ***p < 0.001. Calibration bars:
1 mm in (A), 2 mm (left) and 100 μm (right) in (C).
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TfR2fl/fl:TH-Cre+/− and TfR2fl/fl:TH-Cre−/− PFF-treated ani-
mals (Fig. 5D). Ser129 phospho-synuclein was also assessed
in SNpc DA neurons as a marker of ongoing alpha-synuclein
aggregate pathology. Immunoreactivity for phospho-synuclein
was markedly increased in PFF-injected mice, but the extent
of this increase was not significantly affected by TfR2 deletion
(Fig. 5F).
In summary, these results indicate that targeted TfR2
deletion had neuroprotective effects mostly in female mice
in a synucleinopathy model triggered by PFF injections.
This neuroprotection occurred in the absence of overt
reduction of iron accumulation and despite an overload of
phosphorylated alpha-synuclein.
Discussion
Iron is critical for multiple processes implicated in PD
pathobiology such as mitochondrial function and oxidant
stress. In addition, iron is involved in DNA damage and
repair—being utilized as a cofactor for repair enzymes [35]
as well as catalyzing obnoxious lesions in the double
helix—which also participate in PD pathogenesis and are
mechanistically associated with aging, i.e., PD principal risk
factor [36–39]. Convergent evidence suggests that inter-
vention to prevent iron overload in the SNpc may be a
promising disease modifying approach [40]. Regional
increase of iron in the SNpc of PD patients has been
robustly documented in independent studies [7, 41–44] and
further substantiated by a recent meta-analysis [45]. Con-
sistently, recent clinical trials demonstrated the efficacy of
the iron chelator deferiprone [13, 15]. Because chelation
strategies are imperfect [16], identification of a specific
pharmacological target responsible for iron accumulation
could lay the foundation for more precise intervention.
It is recognized that biomedical research, and neu-
roscience in particular, suffer from a gender bias that should
be urgently corrected to achieve more comprehensive
understanding of disease mechanisms [46–48]. In this
study, we therefore treated male and female animals as
separated experimental groups. Our most salient data
demonstrate that deletion of TfR2 in catecholaminergic
Fig. 3 TfR2 deletion is protective in 52-week-old MPTP-treated
mice. A Striatal TH immunoreactivity in 52-week-old mice. TfR2
deletion provides moderate, yet significant protection from MPTP
treatment. B Unbiased stereological counts of TH immunopositive
neurons in the SNpc confirm that TfR2 deletion is protective in
females, but not in males. C. Perls’ staining for Fe3+ reveals significant
decrease in iron accumulation in the substantia nigra in after MPTP
treatment in animals with TfR2 targeted deletion. In 52-week-old
mice, TfR2 deletion also reduces accumulation of iron deposits in
untreated females. D Double histological staining to reveal Fe3+ in TH
immunopositive neurons in the SNpc, in 12- and 52-week-old mice.
Iron deposits partially co-localize with dopaminergic neurons (arrows).
Iron levels are remarkably more evident in 52-week than in 12-week-
old-treated animals. All data are expressed as percentage of the TfR2fl/
flTH:Cre−/− vehicle-treated control group. Two-tailed Student’s t test;
*p < 0.05, **p < 0.005, ***p < 0.001. Calibration bars: 1 mm in (A),
2 mm in (C) and 50 μm in (D).
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cells—and thus also in the dopamine neurons of the
SNpc—mitigates neuropathology in oxidative stress and
proteotoxic models of PD and reduces the age-related iron
increase in the SNpc. Intriguingly, these effects display
gender dimorphism and are detectable only in females.
The precise mechanisms underlying the differences in
male versus females mice remain to be addressed; the phe-
nomenon, however, is perfectly consistent with gender
dimorphism in both iron metabolism [28, 32, 49] as well as
in PD prevalence and, to some extent, clinical presentation
[50]. A plausible hypothesis is that TfR2 deletion synergizes
with female sex hormones, which are known to mitigate iron-
mediated as well as general cellular oxidant stress, also when
induced by PD-related toxins such as paraquat [27, 51–53].
This hypothesis can be tested in future studies via adminis-
tration of estrogens or castration in males and in ovar-
iectomized females. Indeed, multiple studies demonstrated
a neuroprotective effect of estrogen in the MPTP and
6-hydroxydopamie PD models. Here, the underlying
mechanisms include modulation of the renin–angiotensin
system and of NADPH oxidase activity, possibly culminating
in different activation patterns of microglia and astrocytes to
favor protective over detrimental subtypes [54–59].
The biological reliance of DA neurons on TfR2 and its
consequent role in PD may be related to the distinctive
physiological properties of these cells. Unlike TfR1, TfR2
expression is not reduced upon iron overload by post-
transcriptional mRNA regulation [60] and therefore may
maintain sustained import activity also at high intracellular
iron concentrations. Dopamine neurons may have particular
high iron demand as evidenced, for instance, by the role of
iron as a cofactor in the highly abundant TH enzyme, which
catalyzes the rate limiting step in dopamine biosynthesis, as
well as by the presence of neuromelanin, which functions as
an additional, peculiar iron buffering system [61]. Under
these circumstances, an import mechanism independent of
Fig. 4 Effects of TfR2-targeted deletion in an AAV-h-alpha-
synuclein overexpressing model of PD. A Schematic of intracranial
injection of AAV-h-synuclein in the right SNpc hemisphere (ipsi-
lateral). Transduction with rAAV coding for human alpha-synuclein
(h-syn) results in its striatal increase in the ipsilateral hemisphere, as
showed in the top left panel that is paralleled by decreased TH levels
(bottom left panel) and remarkable Fe3+ deposits accumulation at the
site of injection in the SNpc, indicative of ongoing pathology.
B, C TfR2 deletion does not provide any protection against AAV-h-
synuclein overexpression, as indicated by striatal dopaminergic
innervation expressed as percentage of the contralateral side (B) and
unbiased stereological counts of dopaminergic neurons in the SNpc.
Graphs represent scatter plots with bars. Two-tailed t test. Calibration
bars: 1 mm (top) and 2 mm (bottom) in (A).
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Fig. 5 TfR2-targeted deletion is partially protective against alpha-
synuclein pre-formed fibrils (PFF) intracranial seeding. A Sche-
matic of the stereotactic injection procedure during which PFF have
been injected in the right striatum. B TfR2 deletion provides protection
against striatal denervation induced by PFF, as indicated by TH
immunohistochemistry. C Unbiased stereological counts of dopami-
nergic neurons in the SNpc indicate that TfR2-targeted deletion is
protective against PFF-induced degeneration in females, but not in
males. D Perls’ staining for Fe3+ did not reveal any effect of TfR2
deletion on iron accumulation in the SNpc induced by PFF (left panel).
Immunodetection of TH-positive neurons combined with Perls’
staining reveals iron deposits also in SNpc dopamine neurons (right
panel). E Increased levels of ser129 p-α-synuclein in the substantia
nigra (arrows) confirms α-synuclein stress in PFF-injected animals that
is not ameliorated by TfR2 deletion (green signal). Graphs represent
scatter plots with bars. Two-tailed t test; *p < 0.05, **p < 0.005,
***p < 0.001. Calibration bars: 1 mm in (B), 2 mm (left panel) and
50 μm (right panel) in (D), and 50 μm in (E).
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iron concentration may guarantee effective uptake also
when iron levels are relatively elevated. Dopamine neurons,
however, also display high basal oxidation, which is
intrinsically associated with their physiological properties
[62, 63]. We speculate that this counterintuitive and
potentially harmful biological combination—i.e. elevated
iron, an iron-insensitive import mechanism, and high oxi-
dation—is an example of antagonistic pleiotropy. These
physiological properties may in fact be instrumental for
providing tight regulation of redox signaling—which is
essential for SNpc DA neurons—and thus of the associated
behavior. Overall, these features may offer an advantage
during reproductive stages of life while becoming detri-
mental during aging [64]. If not carefully regulated, for
instance because of aging-related deterioration, this dis-
tinctive physiological layout may easily lead to harmful
consequences, which may be in turn be mitigated by spe-
cific reduction of TfR2-mediated iron uptake.
Our results are also relevant in light of emerging evi-
dence indicating that ferroptosis [65]—an iron-dependent
programmed cell death pathway—may participate in PD
pathogenesis. Ferroptosis, in fact, is associated with cardinal
PD features such as redox imbalance and mitochondrial
dysfunction [66] and requires Tf-mediated iron import [67].
Hampering Tf import to prevent iron overload in DA neu-
rons may therefore provide protection against this type of
cell death mechanism.
Neuroprotection in both young and old MPTP-treated
mice is in agreement with the notion that iron dysregulation
and accumulation may promote oxidative damage via
Fenton chemistry. Protection could occur through redox-
related mechanisms also in the PFF model, consistent with
documented alpha-synuclein ability to promote oxidation
[68]. In fact, the lack of an effect on phospho-synuclein
levels in TfR2 mutants suggests that TfR2 deletion pri-
marily affects mechanisms other than alpha-synuclein
stress. However, additional pathogenic mechanisms speci-
fically related to alpha-synuclein proteotoxic stress may
explain neuroprotection in the PFF model despite lack of
differences in iron deposition. For instance, recent evidence
revealed an interaction between alpha-synuclein oligomer-
ization and stress, and genes involved in the endocytic
pathway [69]. Alterations in endocytosis in the PFF
model—for instance in an attempt to remove toxic oligo-
mers—may therefore be paralleled by undesired increased
uptake of iron. Further studies will be necessary to elucidate
the mechanisms underlying differences in iron accumula-
tion in models of PD-like neurodegeneration based on
oxidant or proteotoxic stress. The negative result observed
in the rAAV mouse model may stem from the high varia-
bility observed in this study, which is consistent with pre-
vious observations using this model [70].
Neuroprotective effects mediated by TfR2 deletion were
more evident at the striatal level rather than in the SNpc,
with improvement in striatal innervation, but no corre-
sponding effect on DA cell body loss. These differential
observations in the striatum and SNpc may be consistent
with the concept that, in PD and PD models, neuritic
pathology precedes frank cell death [71–73]. In addition,
the neuroprotective effect of TfR2 deletion against MPTP is
more pronounced in younger as compared to older female
mice; this evidence is consistent with other reports indi-
cating that, in the MPTP model, neuroprotective molecules
that may indirectly reduce oxidant stress, for instance acting
on dopamine metabolism, are more effective in younger
animals [74].
While the protective effect of TfR2 deletion is moderate,
several elements suggest that its magnitude may improve by
repeating the study in different organisms. For instance, the
biosynthetic pathway of ascorbate, which is also involved in
the brain redox regulation, is intact in mice, while it is lost
in primates and humans [75]. Performing the experiments in
organisms lacking the capacity of ascorbate synthesis might
potentiate the effects of TfR2 deletion. In addition, iron
metabolism differs among mice strains, most likely because
of genetic factors and, for instance, non-heme iron levels are
reduced in some tissues of C57BL/6 mice when compared
to other strains [76]. Repeating the study on a different
strain might amplify the effect of TfR2 deletion, which
could also extend the neuroprotective effect to males,
therefore circumventing the gender issue.
Perls’ staining combined with specific immunodetection
of different cell types to study iron accumulation with
cellular resolution showed iron accumulation in DA neu-
rons, but did not detect differences between wild type and
TfR2fl/fl:TH-Cre+/− mutant mice. These results may point to
insufficient sensitivity of this method. Iron deposition
outside TH+ cells may be explained, at least in part, by
previous evidence from our laboratory indicating that DA
degeneration—which is associated with increased intra-
cellular oxidation, possibly caused by iron overload—is
paralleled by a loss in TH phenotype [77]. Collectively
these elements suggest that, at the observed time points,
cells with detectable ferric iron may have already lost their
neurochemical phenotype. Alternative methods with higher
sensitivity will be required to conclusively address these
issues.
Finally, in male animals reduction in iron levels was not
paralleled by neuroprotection. While this evidence could be
again attributed to limited sensitivity of the Perls’ method, it
could also suggest an iron-independent role for TfR2 in PD
progression. TfR2 is relatively poorly characterized and, at
present and to our best knowledge, potential roles for this
protein outside the iron trafficking domain are unknown.
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Further, in depth studies will be therefore necessary to fully
unravel the mechanisms connecting TfR2, iron levels, and
PR progression.
In conclusion, our study identifies a tractable target to
mitigate neurotoxic iron overload in DA neurons during PD




All reagents were purchased from Sigma-Aldrich unless
otherwise specified.
Animal care
Animals were kept on a regular diet and housed at the
Animal Resource Center (Erasmus University Medical
Center), which operates in compliance with the “Animal
Welfare Act” of the Dutch government, following the
“Guide for the Care and Use of Laboratory Animals” as its
standard.
Transgenic mice expressing recombinase Cre under the
TH promoter [30] were purchased from The Jackson
Laboratory, crossed with TfR2fl/fl mice [29] and kept on
the C57Bl/6J background. Males and females have been
considered as separate experimental groups because in
light of gender dimorphism in iron metabolism
[28, 32, 49], PD prevalence [50], and different sensitivity
to the MPTP drug [78]. Initially, the size of the experi-
mental groups was determined by power analysis; how-
ever, in compliance with the reduction criterion in animal
experimentation and to limit the use of mice, the number
of animals in the experiment group was maintained to the
minimal size required to achieve significance in the pri-
mary outcome measures, i.e., striatal innervation and
stereological counts.
Genomic PCR to confirm TfR2 deletion
To confirm the occurrence of the targeted TfR2 deletion,
genomic DNA analysis was performed on each TfR2fl/flTH:
Cre+/− double mutant and TfR2fl/flTH:Cre−/− mouse used in
the study. Briefly, DNA was extracted from three consecutive
30-µm-thick paraformaldeyde (PFA 4%) fixed sections
derived from the olfactory bulb area [79]. Sections were
incubated in 100mM EDTA, 50mM Tris-HCl, 100mM
NaCl, 1% SDS and 0.15mg/mL proteinase K for 72 h at
65 °C in agitation and protected from light. After 5 min of
centrifugation at 4 °C and 10,000 rpm, the liquid phase was
purified with an equal volume of phenol–chloroform–isoamyl
alcohol (25:24:1) and centrifuged for 10min at 10,000 rpm.
The liquid phase was then washed with chloroform–isoamyl
alcohol (24:1) and then precipitated with 1/10 3M Na-acetate,
pH 5.2 and 2.5 volumes of ethanol. After incubation at
−80 °C, samples were collected by centrifugation and sus-
pended in double distilled water RNAse and DNAse free. The
targeted deletion was identified by PCR using the Platinum
Taq polymerase (10966018, Sigma) and the following pri-
mers: Tfr2-5LoxP-F: 5′-ggggtctacttcggagagtggtaag-3′; TfR2-
5loxP-R: 5′-ctgagggttaggcaagaatggtgt-3′ and TfR2-3loxP-R
5′-ttctgccaacattctetccctctc-3′. The expected fragment sizes
were: 201 bp for WT, 259 bp for TfR2-floxed and 294 bp for
the deletion on the TfR2 allele.
MPTP model
We used the sub-acute paradigm consisting of subcutaneous
injection of 30 mg/kg free base MPTP (M0896, Sigma)
dissolved in PBS or vehicle for 5 consecutive days in 12-
and 52-week-old mice once a day [38]. During the proce-
dure, however, we found that the 30 mg/kg regimen induced
extreme mortality in the 52-week-old animals, and we
therefore reduced the dose to 17.5 mg/kg. This dose was
sufficient to elicit significant DA degeneration without
mortality in the experiment. Animals were finally sacrificed
3 weeks after the last injection, when the degenerative
process was already stabilized [80].
In vitro synthesis of alpha-synuclein pre-formed
fibrils (PFF)
alpha-Synuclein PFF have been generated from human
alpha-synuclein monomer in assembly buffer (PBS, pH 7.0)
as previously described [34, 37, 81]. Briefly, 4 mg of
monomeric α-syn were shacked at 1000 rpm for 7 days at
37 °C. Fibrils were then aliquoted and stored at −80 °C in
single use vials. The efficiency of the fibrillation reaction
was verified with a Thioflavin T (25 µM, Sigma, T 3516)
fluorimeter.
Alpha-synuclein models: stereotaxic injection of
AAV-alpha-synuclein and α-synuclein pre-formed
fibrils (PFF)
Adenoviral-mediated overexpression of human alpha-
synuclein was induced as previously described [33].
Briefly, recombinant adeno-associated virus (serotype 2
genome and serotype 6 capsid, AAV) was used to express
human h-α-syn in the mouse substantia nigra. Gene
expression was under the control of a human Synapsin 1
promoter and enhanced using a woodchuck hepatitis virus
post-transcriptional regulatory element and a polyA signal
downstream to the α-syn sequence. AAV-vector production,
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purification, concentration, and titration were performed by
Sirion (Martinsried, Germany). AAV-synuclein or vehicle
injections were performed at a rate of 0.4 µL/min using a
Hamilton syringe fitted to a glass capillary, under isoflurane
anesthesia. At the end of the procedure, the capillary was left
in site for an additional 5 min before being retracted. Mice
were injected with 1.5 µL of 8.0 × 1012 genome copies/mL
AAV-α-syn into the right substantia nigra, with the fol-
lowing coordinates: 2.3 mm posterior and −1.1 mm lateral
to Bregma, and 4.1 mm ventral to dura mater. Eight mice per
group were used for this study.
PFF injections were performed into the striatum with the
following coordinates: 0.2 mm anterior and 2.0 mm lateral
to Bregma, and 2.6 mm ventral to the dura mater. 2.5 µL of
sonicated PFF (5 µg in sterile PBS) were injected under
isoflurane anesthesia according to standard procedures.
Eight animals per group were used for this study.
Immunohistochemistry
Free floating sections were first incubated in hydrogen
peroxide (H2O2, Sigma-Aldrich, St. Louis, MO, USA) 3%
in PBS for 30 min to block internal peroxidase activity, and
subsequently in PBS-Triton X-100 0.2% (PBS-T) and
normal horse serum (NHS) 10% for 1 h at RT. Specimens
were then incubated for 24 h at 4 °C with mouse mono-
clonal anti-Tyrosine hydroxylase (1:4000, MAB318, Mil-
lipore, MA, USA) or with affinity purified anti human
alpha-synuclein (1:3000, AB5038P, Millipore, Germany) in
PBS-T and 1.5% NHS. After several washes with PBS-T,
sections were incubated with biotinylated goat anti-rabbit
IgG (1:500; BA 1000, Vector Laboratories, Burlingame,
CA, USA), in PBS and 1% NHS for 1 h at RT. Immuno-
complexes were revealed by Vectastain Elite ABC kit (PK
4000, Vector Laboratories, Burlingame, CA, USA), using
3,3′-diamino-benzidine (DAB Substrate kit for Peroxidase,
SK 4100, Vector Laboratories, Burlingame, CA, USA) or
by alkaline phosphatase (BCIP/NBT substrate alkaline
phosphatase kit, SK5400, Vector Laboratories, Burlingame,
CA, USA). Finally, sections were dehydrated and mounted
with Eukitt (Kindler GmbH & Co). Images were acquired
with the Nanozoomer 2.0 HT digital slide scanner and
analyzed with the NDP viewer software (Hamamatsu).
Quantification of striatal TH density
Striatal lesions in DAB-stained sections were calculated as
the extension of the lesioned area, detected by the absence
of TH staining, and expressed as percentage of TH immu-
nopositive area measured on the contralateral side (for the
AAV model) or on the PBS control mice (for the PFF
model). A total of ten sections per animals were analyzed.
Immunofluorescence
In immunofluorescence experiments, tissue sections were
processed as described in the immunohistochemistry section
with minor modifications. Floating sections were incubated
overnight at 4 °C with primary antibodies. The following
antibodies were used: mouse monoclonal anti-Tyrosine
Hydroxylase (1:4000, MAB318, Millipore), sheep polyclonal
anti-Tyrosine Hydroxylase (1:4000; NB300-110, Novus Bio-
logicals), anti-phospho-α-Synuclein (S129; 1:1000; ab59264,
Millipore, Germany), anti-MAC2 (1:1000; CL8942AP, Mil-
lipore), anti–GFAP (AB7260, 1:2000 Abcam).
Tissue sections were rinsed with PBS and then incubated
for 2 h at RT in TBS containing 0.4% Triton X-100, 2%
NHS, Alexa488 conjugated donkey anti-rabbit IgG 1:500
(Invitrogen), Alexa594 conjugated donkey anti-mouse IgG
1:500 (Invitrogen), CY3 conjugated anti-sheep IgG (1:500,
Jackson). Image acquisition was performed with a Leica
TCS SP5 confocal microscope.
Unbiased stereological counts
Unbiased stereological estimation of the total number of DA
cells in SNpc was performed using the optical fractionator
method [82] and the STEREO INVESTIGATOR program
on a Neurolucida computer-controlled microscopy system
(Microbrightfield Inc., Williston, VT, USA). The edges of
the SNc in the rostro-caudal axis were defined at all levels,
with reference to a coronal atlas of the mouse brain [83].
TH-positive cells in the SNc of both hemispheres were
counted in three sections, on comparable sections for all the
subgroups of treatment throughout the entire nucleus.
Counting frames (60 × 60 µm) were placed at the intersec-
tions of a grid (frame size 120 × 120 µm) that was randomly
placed over the section. For counting, only those counting
frames in which at least a part of the frame fell within the
contour of the SNpc were used. TH-positive cell bodies were
marked only if in focus. Guard volumes (3 µm from the top
and 3 µm from the bottom of the section) were excluded
from both surfaces to avoid the problem of lost caps. The
reliability of the estimate was assessed by calculation of the
coefficient of error as previously described [84].
DAB enhanced Perls staining for ferric iron
To detect Fe3+ iron content, slices were washed two times
with phosphate buffer (PB) 0.1 M and then incubated with
equal volumes of HCl 20% and potassium ferrocynide
(K4Fe(CN)6 × 3·H2O) 10% for 40 min to release Fe
3+. After
three washes in PB 0.1 M, sections were treated with NaN3
0.01M and H2O2 3% in PB 0.1 M for 15 min to inactivate
endogenous peroxidases. After two washes with PB 0.1 M
C. Milanese et al.
and two following with 0.05M Tris-HCl, iron accumulation
was revealed with 3,3′-diamino-benzidine (DAB Substrate
kit for Peroxidase, SK 4100, Vector Laboratories, Burlin-
game, CA, USA) containing H2O2 0.005% for 50 min.
Slices were then washed two times with Tris-HCl 0.05M
and two times with PB 0.1M before drying and being
mounted with Eukitt (Kindler GmbH & Co.) or processed
for immunohistochemistry as described above. Images were
acquired with the Nanozoomer 2.0 HT digital slide scanner
and analyzed with the NDP viewer software (Hamamatsu).
Statistical analysis
Experiments were performed at least in three independent
biological and at least two independent technical replicates.
All analyses were performed using Graph Pad Prism version
7.03 for Windows (GraphPad Software, La Jolla, CA,
USA). P values expressed as *P < 0.05; **P < 0.01, ***P <
0.001 were considered to be statistically significant; in the
absence of indications, comparisons should be considered
non-significant. Comparisons for two groups were calcu-
lated by unpaired two-tailed Student’s t tests and compar-
isons for more than two groups were calculated by either
one- or two-way analysis of variance respectively followed
by Dunnett’s and Bonferroni post-hoc test. All values are
expressed as mean ± SEM.
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